180 related articles for article (PubMed ID: 29265937)
1. Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P
Lopez ES; Ortiz GA; Potilinski C; Croxatto JO; Gallo JE
Curr Eye Res; 2018 Apr; 43(4):466-473. PubMed ID: 29265937
[TBL] [Abstract][Full Text] [Related]
2. Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.
Lopez ES; Rizzo MM; Croxatto JO; Mazzolini G; Gallo JE
Cancer Chemother Pharmacol; 2011 Mar; 67(3):723-8. PubMed ID: 20857116
[TBL] [Abstract][Full Text] [Related]
3. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
4. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
7. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).
Azar DT
Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348
[TBL] [Abstract][Full Text] [Related]
8. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
9. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
10. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of corneal neovascularization by rapamycin.
Kwon YS; Kim JC
Exp Mol Med; 2006 Apr; 38(2):173-9. PubMed ID: 16672771
[TBL] [Abstract][Full Text] [Related]
12. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
14. Critical Role of IP-10 on Reducing Experimental Corneal Neovascularization.
Liu G; Zhang W; Xiao Y; Lu P
Curr Eye Res; 2015 Sep; 40(9):891-901. PubMed ID: 25309995
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
16. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
[TBL] [Abstract][Full Text] [Related]
17. Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo.
Sharma A; Bettis DI; Cowden JW; Mohan RR
Mol Vis; 2010 Apr; 16():720-8. PubMed ID: 20431722
[TBL] [Abstract][Full Text] [Related]
18. KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.
Li T; Hu A; Li S; Luo Y; Huang J; Yu H; Ma W; Pan J; Zhong Q; Yang J; Wu J; Tang S
Mol Vis; 2011 Mar; 17():797-803. PubMed ID: 21528000
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of topical bevacizumab and sorafenib in experimental corneal neovascularization.
Yildirim H; Aydemir O; Balbaba M; Özercan İH; İlhan N
Cutan Ocul Toxicol; 2020 Sep; 39(3):223-228. PubMed ID: 32338080
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic effect of KR-31831 on corneal and choroidal neovascularization in rat models.
Kim IT; Park HY; Choi JS; Joo CK
Invest Ophthalmol Vis Sci; 2012 May; 53(6):3111-9. PubMed ID: 22491414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
